Investigational Semaglutide Biosimilar Undergoes Phase III Trial Against WEGOVY® in Chinese Obese Patients

Obesity represents a formidable global health challenge, significantly elevating the risk for severe comorbidities such as type 2 diabetes mellitus, hypertension, dyslipidemia, cardiovascular disease, and certain types of cancer. While lifestyle modifications remain foundational, pharmacological interventions, particularly glucagon-like peptide-1 receptor (GLP-1R) agonists like semaglutide (WEGOVY®), have revolutionized weight management with their proven efficacy in achieving substantial and sustained weight loss. However, the premium pricing and patent protection of branded GLP-1R agonists often limit their accessibility, creating a significant unmet need for more affordable options, especially in populous regions like China. The development and rigorous clinical evaluation of biosimilars are therefore critical to broaden patient access, reduce healthcare costs, and ensure equitable availability of these transformative treatments for obesity and its associated metabolic dysfunctions. This Phase III study directly addresses this gap by comparing a novel biosimilar to the established reference product.

This is a 48-week, randomized, open-label, parallel-controlled Phase III clinical trial meticulously designed to assess the comparative efficacy, safety, and immunogenicity of an investigational semaglutide injection biosimilar against the reference product, WEGOVY® injection, in adult Chinese patients diagnosed with obesity. Participants meeting eligibility criteria will be randomized in a 1:1 ratio to receive either the experimental biosimilar or WEGOVY®. Both groups will undergo once-weekly subcutaneous injections for a total of 44 weeks, followed by a dedicated 4-week safety follow-up period to monitor for adverse events and immunogenic responses. Crucially, all enrolled participants will concurrently receive comprehensive lifestyle intervention counseling, encompassing guidance on dietary modifications and increased physical activity, ensuring a standardized non-pharmacological baseline. Primary endpoints include changes in body weight, while secondary endpoints will evaluate various metabolic parameters and the incidence of treatment-emergent adverse events.